Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03639948 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer
A Phase 2 study of Triple Negative Breast Cancer, sponsored by University of Kansas Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 9
- Study locations
NCT03639948 is a Phase 2 study of Triple Negative Breast Cancer that is active but no longer recruiting, run by University of Kansas Medical Center. The registered enrollment target is 120 participants, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (51% lower). The trial reports 9 study locations across 3 states.
The verdict
NCT03639948, a Phase 2 study of Triple Negative Breast Cancer, is active but no longer recruiting, sponsored by University of Kansas Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 9
- Study locations
Study Summary
The standard treatment for women with stage I, II, and III triple-negative breast cancer (TNBC) includes chemotherapy and surgery, with or without radiation therapy. However, because TNBC is usually more aggressive, harder to treat, and more likely to come back, it is associated with poor long-term outcomes (survival rates) when compared to other types of breast cancer. Therefore, researchers are studying how new drugs and treatment combinations can improve the outcome of patients with TNBC. This study will test effectiveness of immune therapy (Pembrolizumab is an "immunotherapy" that is expected to work with the body's immune system to help fight cancer) in combination with chemotherapy given before surgery.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Docetaxel
- DRUG Pegfilgrastim
Study Locations (9)
Kansas
- The University of Kansas Cancer Center (KUCC) - Fairway
- The University of Kansas Cancer Center, West Clinic - Kansas City
- The University of Kansas Cancer Center, Westwood Campus - Kansas City
- University of Kansas Cancer Center - Kansas City
- The University of Kansas Cancer Center, Overland Park Clinic - Overland Park
Missouri
- The University of Kansas Cancer Center, North Clinic - Kansas City
- The University of Kansas Cancer Center, Lee's Summit Clinic - Lee's Summit
- The University of Kansas Medical Center - North Kansas City
Texas
- Texas Oncology- Baylor - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2018-09-04 |
| Est. Completion | 2024-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03639948
The ClinicalTrials.gov registry entry for NCT03639948 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (51% lower). The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Triple Negative Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT03639948 reports 9 study locations spanning 3 distinct geographic areas - top geographies include Kansas, Missouri, Texas.
Frequently Asked Questions
What is clinical trial NCT03639948 about?
NCT03639948 is a clinical study titled "Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer". The standard treatment for women with stage I, II, and III triple-negative breast cancer (TNBC) includes chemotherapy and surgery, with or without radiation therapy. However, because TNBC is usually more aggressive, harder to treat, and more likely to come back, it is associated with poor long-term ...
What is the current status of trial NCT03639948?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2018-09-04. Estimated completion is 2024-11.
What conditions does trial NCT03639948 study?
This clinical trial studies the following conditions: Triple Negative Breast Cancer.
What interventions are being tested in trial NCT03639948?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Docetaxel (DRUG), Pegfilgrastim (DRUG).
Who is sponsoring clinical trial NCT03639948?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03639948 being conducted?
This trial has 9 study locations across Kansas, Missouri, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Triple Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients
RECRUITING · Phase 2
-
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RECRUITING · Phase 2
-
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.